{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:18Z","timestamp":1794047478909,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability of response remains a concern. We hypothesize that targeting both BCL2 and B-cell lymphoma-extra large (BCLXL) will be a successful strategy to treat CLL, including for patients who relapse on venetoclax. To test this hypothesis, we conducted a pre-clinical investigation of LP-118, a highly potent inhibitor of BCL2 with moderate BCLXL inhibition to minimize platelet toxicity. This study demonstrated that LP-118 induces efficient BAK activation, cytochrome C release, and apoptosis in both venetoclax-na\u00efve and -resistant CLL cells. Significantly, LP-118 is effective in cell lines expressing the BCL2 G101V mutation and in cells expressing BCLXL but lacking BCL2 dependence. Using an immunocompetent mouse model, E\u03bc-TCL1, LP-118 demonstrates low platelet toxicity, which hampered earlier BCLXL inhibitors. Finally, LP-118 in the RS4;11 and OSU-CLL xenograft models results in decreases in tumor burden and survival advantage, respectively. These results provide a mechanistic rationale for the evaluation of LP-118 for the treatment of venetoclax-responsive and -relapsed CLL.<\/jats:p>","DOI":"10.3324\/haematol.2023.284353","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T11:26:05Z","timestamp":1723116365000},"page":"78-91","source":"Crossref","is-referenced-by-count":15,"title":["LP-118 is a novel B-cell lymphoma 2 \/ extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Janani","family":"Ravikrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy Y.","family":"Diaz-Rohena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Muhowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Huei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrilekha","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmelle D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Satpati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tierney","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arletta","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KerryA","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenlai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"70801","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"70802","doi-asserted-by":"crossref","unstructured":"Fischer K, Al-Sawaf O, Bahlo J. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380(23):2225-2236.","DOI":"10.1056\/NEJMoa1815281"},{"key":"70803","doi-asserted-by":"crossref","unstructured":"Tausch E, Close W, Dolnik A. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019; 104(9):e434-e437.","DOI":"10.3324\/haematol.2019.222588"},{"key":"70804","doi-asserted-by":"crossref","unstructured":"Blombery P, Thompson ER, Nguyen T. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020; 135(10):773-777.","DOI":"10.1182\/blood.2019004205"},{"key":"70805","doi-asserted-by":"crossref","unstructured":"Blombery P, Anderson MA, Gong JN. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019; 9(3):342-353.","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"70806","doi-asserted-by":"crossref","unstructured":"Lucas F, Larkin K, Gregory CT. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/ PLCG2 mutations. Blood. 2020; 135(24):2192-2195.","DOI":"10.1182\/blood.2019003722"},{"key":"70807","doi-asserted-by":"crossref","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D. Mitochondrial reprogramming underlies resistance to BCL2 inhibition in lymphoid malignancies. Cancer Cell. 2019; 36(4):369-384.e13.","DOI":"10.1016\/j.ccell.2019.08.005"},{"key":"70808","doi-asserted-by":"crossref","unstructured":"Herling CD, Abedpour N, Weiss J. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018; 9(1):727.","DOI":"10.1038\/s41467-018-03170-7"},{"key":"70809","doi-asserted-by":"crossref","unstructured":"Thijssen R, Diepstraten ST, Moujalled D. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021; 137(20):2721-2735.","DOI":"10.1182\/blood.2020010167"},{"key":"70810","doi-asserted-by":"crossref","unstructured":"Thijssen R, Tian L, Anderson MA. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022; 140(20):2127-2141.","DOI":"10.1182\/blood.2022016040"},{"key":"70811","doi-asserted-by":"crossref","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S. MCL1 and BCLXL-dependent resistance to the BCL2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015; 6(1):e1593-e1593.","DOI":"10.1038\/cddis.2014.525"},{"key":"70812","doi-asserted-by":"crossref","unstructured":"Haselager M, Thijssen R, West C. Regulation of Bcl-XL by non-canonical NF-kB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021; 28(5):1658-1668.","DOI":"10.1038\/s41418-020-00692-w"},{"key":"70813","doi-asserted-by":"crossref","unstructured":"Haselager MV, Kielbassa K, Ter Burg J. Changes in BCL2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020; 136(25):2918-2926.","DOI":"10.1182\/blood.2019004326"},{"key":"70814","doi-asserted-by":"crossref","unstructured":"Yuda J, Will C, Phillips DC. Selective MCL1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023; 3(1):154.","DOI":"10.1038\/s43856-023-00380-z"},{"key":"70815","doi-asserted-by":"crossref","unstructured":"Wang X, Bathina M, Lynch J. Deletion of MCL1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013; 27(12):1351-1364.","DOI":"10.1101\/gad.215855.113"},{"key":"70816","doi-asserted-by":"crossref","unstructured":"Wei AH, Roberts AW, Spencer A. Targeting MCL1 in hematologic malignancies: rationale and progress. Blood Rev. 2020; 44:100672.","DOI":"10.1016\/j.blre.2020.100672"},{"key":"70817","doi-asserted-by":"crossref","unstructured":"Roberts AW, Seymour JF, Brown JR. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012; 30(5):488-496.","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"70818","doi-asserted-by":"crossref","unstructured":"Kipps TJ, Eradat H, Grosicki S. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2826-2833.","DOI":"10.3109\/10428194.2015.1030638"},{"key":"70819","doi-asserted-by":"crossref","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021; 11(6):1440-1453.","DOI":"10.1158\/2159-8290.CD-20-1465"},{"key":"70820","doi-asserted-by":"crossref","unstructured":"Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013; 61(2):156-164.","DOI":"10.1016\/j.ymeth.2013.04.006"},{"key":"70821","doi-asserted-by":"crossref","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-185.","DOI":"10.1016\/j.ccr.2007.07.001"},{"key":"70822","doi-asserted-by":"crossref","unstructured":"Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE. Potent and specific peptide inhibitors of human pro-survival protein BCLXL. J Mol Biol. 2015; 427(6 Pt B):1241-1253.","DOI":"10.1016\/j.jmb.2014.09.030"},{"key":"70823","doi-asserted-by":"crossref","unstructured":"Moore VDG, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007; 117(1):112-121.","DOI":"10.1172\/JCI28281"},{"key":"70824","doi-asserted-by":"crossref","unstructured":"Kater AP, Slinger E, Cretenet G. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021; 5(23):5410-5414.","DOI":"10.1182\/bloodadvances.2021004861"},{"key":"70825","doi-asserted-by":"crossref","unstructured":"Ten Hacken E, Valentin R, Regis FFD. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018; 3(19):e121438.","DOI":"10.1172\/jci.insight.121438"},{"key":"70826","doi-asserted-by":"crossref","unstructured":"Hertlein E, Beckwith KA, Lozanski G. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One. 2013; 8(10):e76607.","DOI":"10.1371\/journal.pone.0076607"},{"key":"70827","doi-asserted-by":"crossref","unstructured":"Mato AR, Roeker LE, Jacobs R. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020; 26(14):3589-3596.","DOI":"10.1158\/1078-0432.CCR-19-3815"},{"key":"70828","doi-asserted-by":"crossref","unstructured":"Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020; 11(7):556.","DOI":"10.1038\/s41419-020-02760-y"},{"key":"70829","doi-asserted-by":"crossref","unstructured":"Keitel U, Scheel A, Thomale J. BCLXL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget. 2014; 5(23):11778-11791.","DOI":"10.18632\/oncotarget.2634"},{"key":"70830","doi-asserted-by":"crossref","unstructured":"Zhang YL, Pang LQ, Wu Y, Wang XY, Wang CQ, Fan Y. Significance of BCLXL in human colon carcinoma. World J Gastroenterol. 2008; 14(19):3069-3073.","DOI":"10.3748\/wjg.14.3069"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284353\/77457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284353\/77941","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11714\/77457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:09Z","timestamp":1794046029000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284353","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}